EV

Evogene LtdNASDAQ EVGN Stock Report

Last reporting period 30 Jun, 2024

Updated 26 Nov, 2024

Last price

Market cap $B

0.013

Micro

Exchange

XNAS - Nasdaq

EVGN Stock Analysis

EV

Uncovered

Evogene Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-39/100

Low score

Market cap $B

0.013

Dividend yield

Shares outstanding

41.244 B

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

View Section: Eyestock Rating